source
- FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plungeThe U.S. Food and Drug Administration issued a partial clinical hold on BMB-101, an experimental seizure treatment from Bright Minds Biosciences, after regulators identified toxicity concerns in pr…
- Karyopharm files Chapter 11 and taps Irish biotech Ayrmid as lead bidder for mergerKaryopharm Therapeutics, a Massachusetts-based biopharma, entered Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech Ayrmid. The move follows a cash crisis revealed in…